Everything below concerns human growth hormone. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-07-29. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
== Products == In Germany and Austria, spelt loaves and rolls (Dinkelbrot) are widely available in bakeries. The unripe spelt grains are dried and eaten as Grünkern ("green grain"). In Australia it is grown organically for the health food market. Dutch jenever makers sometimes distil with spelt, while beer brewed from spelt exists in Bavaria and Belgium.
== In culture == Although observations of soy consumption inducing gynecomastia on men are not conclusive, a pejorative term, "soy boy", has emerged to describe perceived emasculated young men with feminine traits.
The American National Library of Medicine also stated in an article in 2018 that the consequences of FGM/C have both physiological and psychological complications, including short- and long-term complications. The method in which the procedure is performed may determine the extent of the short-term complications. If the process was completed using unsterile equipment, no antiseptics, and no antibiotics, the victim may have increased risk of complications. Primary infections include staphylococcus infections, urinary tract infections, excessive and uncontrollable pain, and hemorrhaging. Infections such as human immunodeficiency virus (HIV), Chlamydia trachomatis, Clostridium tetani, and herpes simplex virus (HSV) 2 are significantly more common among women who underwent Type 3 mutilation compared with other categories.
Sources: en.wikipedia.org
Positron emission tomography imaging studies have reportedly found that tramadol levels are at least four-fold higher in the brain than in plasma. Conversely, brain levels of desmetramadol "only slowly approach those in plasma". The plasma protein binding of tramadol is only 4–20%; hence, almost all tramadol in circulation is free, thus bioactive.
Pemetrexed, sold under the brand name Alimta among others, is a chemotherapy medication for the treatment of pleural mesothelioma and non-small cell lung cancer (NSCLC). It is available as a generic medication.
The analyte is already in an ion form in the solution, and it is desorbed as the solvent evaporates. Acid-base transfer. If the solvent is a buffer solution, then the analyte can ionize by exchanging a proton with the buffer. This form of ionization is well-suited for LC-MS, since the liquid used in liquid chromatography already is a buffer solution. Plasmaspray ionization or filament-on operation. The solvent in the spray is electron-ionized by an energetic electron beam. The ionized solvent then chemically ionizes the analyte. In ESI, the solution enters a capillary held at a high voltage (usually 2-5 kV), producing an electrospray into a heated chamber against a counterflow of a drying gas (usually nitrogen). This evaporates solvent molecules. The charge density increases on a droplet as it evaporates, until the electrostatic energy overcomes the surface tension energy, exploding the droplet. This process repeats, ending with an ion stream without the solvent. The ionization can occur by:
The shallot ( or ) is a cultivar group of the onion. Until 2010, the (French red) shallot was classified as a separate species, Allium ascalonicum. The taxon was synonymized with Allium cepa (the common onion) in 2010, as the difference was too small to justify a separate species. As part of the onion genus Allium, its close relatives include garlic, scallions, leeks, chives, and the Chinese onion.
Sources: en.wikipedia.org
The trypsin, once activated, can also cleave other trypsinogens as well as the precursors of other proteases such as chymotrypsin and carboxypeptidase to activate them. In bacteria, a similar strategy of employing an inactive zymogen or prezymogen is used. Subtilisin, which is produced by Bacillus subtilis, is produced as preprosubtilisin, and is released only if the signal peptide is cleaved and autocatalytic proteolytic activation has occurred.
=== Flash column chromatography === In 1978, Still and coworkers published a highly influential paper reporting a purification technique known as flash column chromatography. Prior to this report, column chromatography using silica gel as a stationary phase had already been established as a valuable method for the separation and purification of organic compounds. However, elution of the solvent by gravity alone was often a tedious process, requiring several hours and leading to poor separations due to band broadening via diffusion. Still's innovation was to apply pressure to the top of the column to increase the speed of solvent elution. Not only did this drastically reduce the time required to run the column, but it also allowed for the routine separation of compounds having an Rf difference of 0.10 or greater. After optimizing this procedure, Still compiled a table correlating column diameter, volume of eluant, amount of sample, and typical fraction size, providing a useful guide for application of this technique in the laboratory. Today, flash column chromatography is one of the most important methods for the purification of organic compounds, especially when working on a small scale (< 50 mg) where the techniques of recrystallization and distillation are impractical. Still's paper describing flash column chromatography remains his most highly cited publication and holds the distinction of being one of the most frequently downloaded papers from the Journal of Organic Chemistry, despite being published over 35 years ago.
For services to Punjabi and Sikh Heritage, and to Charity. Wayne Ellis Griffiths. Chair, Macmillan's Wales Volunteer Forum and Ambassador and Fundraiser, Velindre Cancer Centre. For services to Fundraising for Cancer Care and Cancer Research. Clare Eluned Frances Gummett. For services to the community in the London Borough of Merton. Eileen Hagan. Volunteer, Blackpool Support Adult Services Unit, Scouts Movement. For services to Young People and to the community in Blackpool. Ian Robert Hague. For services to the community in Sheffield, South Yorkshire. Graham Nelson Hall. Vice President, Nottinghamshire Football Association Ltd. For services to Young People and Sport. Godfrey Williams Harrison. For services to the community in Bude-Stratton, Cornwall. Martin Dymock Harrison. For services to the community in Royal Leamington Spa, Warwickshire and the West Midlands. Stephen Michael Harrison. For services to the Church and to the community in South Petherton, Somerset. Shendl Hastings Harvey (Shendl Russell). Teacher and Dancer, Royal Scottish Official Board of Highland Dancing. For services to Dance. David Kingsley Hastings. Branch Secretary, Royal National Lifeboat Institution Durham Fundraising Branch and Community Presenter. For voluntary services to the Royal National Lifeboat Institution. Nicola June Hawkins. For services to the community in Hastings and Rother, East Sussex. Tracy Hawkins. Assistant Secretary, Special Air Service Regimental Association. For Charitable Services. John Bertram Heasman. President, Dulwich Unit.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.